AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Hyperfine, Inc.
Video analysis: HYPR
All videosNo video analysis for this stock yet. Request one from our team.
News: HYPR
Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents
GUILFORD, Conn.--(BUSINESS WIRE)--Completion of enrollment in study to support anticipated indication expansion for use of the Swoop® system with contrast agents.
Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced plans to participate in the upcoming Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on Thursday, September 10th. Management will be hosting in-person meetings. To schedule a meeting with management, please reach out to your Lak.
Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans
[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered
Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans
GUILFORD, Conn.--(BUSINESS WIRE)--Peer-reviewed NEURO PMR results and 3,000+ office brain MRI scans support growing use of the Swoop system across neurology practices.
Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings
[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered
Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings
GUILFORD, Conn.--(BUSINESS WIRE)--FDA-cleared Optive AI software enhances Swoop system image quality, clinical utility, ease of use, and isotropic imaging capability.
Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript
Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript
Hyperfine Q2 Earnings Call Highlights
Hyperfine NASDAQ: HYPR reported second-quarter revenue of $3.9 million, up approximately 45% from a year earlier, as the portable MRI company cited growth across hospital, neurology office and international markets.
